FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3015763287> ?p ?o ?g. }

• W3015763287 endingPage "e000695" @default.
• W3015763287 startingPage "e000695" @default.
• W3015763287 abstract "The immune system evolved for adequate surveillance and killing of pathogens while minimizing host damage, such as due to chronic or exaggerated inflammation and autoimmunity. This is achieved by negative regulators and checkpoints that limit the magnitude and time course of the immune response. Tumor cells often escape immune surveillance and killing. Therefore, disrupting the brakes built into the immune system should effectively boost the anticancer immune response. The success of anti-CTLA4, anti-PD-1 and anti-PD-L1 have firmly established this proof of concept. Since the response rate of anti-CTLA4, anti-PD-1 and anti-PD-L1 is still limited, there is an intense effort for the identification of new targets and development of approaches that can expand the benefits of immunotherapy to a larger patient pool. Additional T cell checkpoints are obvious targets; however, here we focus on the unusual suspects—cells that function to initiate and guide T cell activity. Innate immunity is both an obligate prerequisite for the initiation of adaptive immune responses and a requirement for the recruitment of activated T cells to the site of action. We discuss some of the molecules present in innate immune cells, including natural killer cells, dendritic cells, macrophages, myeloid-derived suppressor cells, endothelial cells and stromal cells, that can activate or enhance innate immune cell functions, and more importantly, the inhibitors or checkpoints present in these cells that restrain their functions. Boosting innate immunity, either by enhancing activator functions or, preferably, by blocking the inhibitors, may represent a new anticancer treatment modality or at least function as adjuvants to T cell checkpoint inhibitors." @default.
• W3015763287 created "2020-04-17" @default.
• W3015763287 creator A5023260904 @default.
• W3015763287 creator A5082732480 @default.
• W3015763287 date "2020-04-01" @default.
• W3015763287 modified "2023-10-17" @default.
• W3015763287 title "Lifting the innate immune barriers to antitumor immunity" @default.
• W3015763287 cites W1498931318 @default.
• W3015763287 cites W1954516783 @default.
• W3015763287 cites W1966217032 @default.
• W3015763287 cites W1966280572 @default.
• W3015763287 cites W1971896241 @default.
• W3015763287 cites W1971985122 @default.
• W3015763287 cites W1972452655 @default.
• W3015763287 cites W1981552113 @default.
• W3015763287 cites W1982084822 @default.
• W3015763287 cites W1987062630 @default.
• W3015763287 cites W1992088744 @default.
• W3015763287 cites W1996032846 @default.
• W3015763287 cites W2003244776 @default.
• W3015763287 cites W2006073656 @default.
• W3015763287 cites W2007501395 @default.
• W3015763287 cites W2007820695 @default.
• W3015763287 cites W2010329820 @default.
• W3015763287 cites W2012739993 @default.
• W3015763287 cites W2012836981 @default.
• W3015763287 cites W2014349052 @default.
• W3015763287 cites W2016642619 @default.
• W3015763287 cites W2018118610 @default.
• W3015763287 cites W2022270308 @default.
• W3015763287 cites W2026733939 @default.
• W3015763287 cites W2026861011 @default.
• W3015763287 cites W2027615892 @default.
• W3015763287 cites W2029184645 @default.
• W3015763287 cites W2029733235 @default.
• W3015763287 cites W2032724602 @default.
• W3015763287 cites W2033577259 @default.
• W3015763287 cites W2038914273 @default.
• W3015763287 cites W2040777459 @default.
• W3015763287 cites W2043765645 @default.
• W3015763287 cites W2044757050 @default.
• W3015763287 cites W2046348840 @default.
• W3015763287 cites W2046505430 @default.
• W3015763287 cites W2046768931 @default.
• W3015763287 cites W2048253455 @default.
• W3015763287 cites W2049553585 @default.
• W3015763287 cites W2050315807 @default.
• W3015763287 cites W2051618227 @default.
• W3015763287 cites W2051692881 @default.
• W3015763287 cites W2052853635 @default.
• W3015763287 cites W2053941041 @default.
• W3015763287 cites W2055279578 @default.
• W3015763287 cites W2055901890 @default.
• W3015763287 cites W2059492353 @default.
• W3015763287 cites W2060672294 @default.
• W3015763287 cites W2062761137 @default.
• W3015763287 cites W2069468418 @default.
• W3015763287 cites W2070636596 @default.
• W3015763287 cites W2070968699 @default.
• W3015763287 cites W2071456955 @default.
• W3015763287 cites W2073303594 @default.
• W3015763287 cites W2073359588 @default.
• W3015763287 cites W2078308178 @default.
• W3015763287 cites W2079068389 @default.
• W3015763287 cites W2080886891 @default.
• W3015763287 cites W2081717004 @default.
• W3015763287 cites W2085878503 @default.
• W3015763287 cites W2086834665 @default.
• W3015763287 cites W2090020016 @default.
• W3015763287 cites W2093194698 @default.
• W3015763287 cites W2096294540 @default.
• W3015763287 cites W2097063436 @default.
• W3015763287 cites W2097126393 @default.
• W3015763287 cites W2097690601 @default.
• W3015763287 cites W2103746815 @default.
• W3015763287 cites W2104388996 @default.
• W3015763287 cites W2104885590 @default.
• W3015763287 cites W2105440238 @default.
• W3015763287 cites W2110342824 @default.
• W3015763287 cites W2111415894 @default.
• W3015763287 cites W2113863168 @default.
• W3015763287 cites W2114206805 @default.
• W3015763287 cites W2114643906 @default.
• W3015763287 cites W2114853101 @default.
• W3015763287 cites W2124416339 @default.
• W3015763287 cites W2126020984 @default.
• W3015763287 cites W2129449960 @default.
• W3015763287 cites W2132089284 @default.
• W3015763287 cites W2132413371 @default.
• W3015763287 cites W2134528462 @default.
• W3015763287 cites W2137500094 @default.
• W3015763287 cites W2141186092 @default.
• W3015763287 cites W2142541925 @default.
• W3015763287 cites W2143113950 @default.
• W3015763287 cites W2143523733 @default.
• W3015763287 cites W2143772132 @default.
• W3015763287 cites W2146261880 @default.
• W3015763287 cites W2153232526 @default.

• next